The Alzheimer’s Association has published an analysis of a 2024 RAND report that outlines the health, community, and economic benefits of more systemic and deliberate investment in the treatment of Alzheimer’s disease in adults with Down syndrome.
Tips on how to protect yourself and others from COVID-19Source: Centers for Diesease Control and Prevention (CDC)
10/1/2024 | For immediate release | Contact: Kate O’Neill ([email protected]) Investment in Alzheimer’s Research Today Will Yield Health Benefits for
Information on the COVID-19 vaccinationsSource: Center for Disease Control and Prevention (CDC)
Project will empower advocates, enhance research for people at high risk of Alzheimer’s disease who have Down syndrome Washington, D.C.
Information revealed at the 2024 AAIC conference on the ACTC-DS-led study in DS-associated Alzheimer’s disease with Lilly’s anti-amyloid drug Kisunla.
In honor of Collin Lis, a kind and loving 11-year-old boy with Down syndrome, LuMind IDSC is presenting the Collin
FDA issues approval for Kisunla, new Alzheimer’s drug; Down syndrome community optimistic On Tuesday, July 2, the U.S. Food and
Major pharmaceutical company announces Down syndrome population will see a clinical trial of new Alzheimer’s drug People with Down syndrome
This graphic answers several FAQs about the Down Syndrome Medical Interest Group (DSMIG) Project ECHO.Source: DSMIG-USA
